Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
- According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A treatment Hemlibra.
- The new safety data from the Phase 3b STASEY study revealed that Hemlibra was effective with no new safety signals identified in adults and adolescents with hemophilia A with factor VIII inhibitors.
- The final analysis included data from 193 hemophilia A patients who received Hemlibra prophylaxis once weekly for up to two years.
- The analysis did not show any new cases of thrombotic microangiopathy or severe thrombotic events related to Hemlibra.
- In addition, the STASEY study reinforced that Hemlibra is associated with a low incidence of anti-drug antibody (ADA) development.
- Ten (5.2%) participants tested positive for ADAs, five (2.6%) of whom were classified as having ADAs that were neutralizing in vitro.
- In all 10 participants, ADA development did not affect the efficacy or safety of Hemlibra.
- Hemlibra demonstrated effective bleed control, with 82.6% of participants experiencing no bleeding episodes that required treatment.
- Annualized bleeding rates were consistent with previously reported observations from the pivotal HAVEN studies.
- Price Action: RHHBY shares closed at $48.63 on Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Hemophilia ABiotech News Health Care General
